hVIVO (LON:HVO) Trading Up 21.1% - What's Next?

hVIVO plc (LON:HVO - Get Free Report)'s share price was up 21.1% during mid-day trading on Monday . The stock traded as high as GBX 11 ($0.15) and last traded at GBX 10.54 ($0.14). Approximately 41,658,949 shares traded hands during trading, an increase of 999% from the average daily volume of 3,792,246 shares. The stock had previously closed at GBX 8.70 ($0.12).

Analyst Upgrades and Downgrades

Separately, Shore Capital reiterated a "buy" rating on shares of hVIVO in a research report on Friday, May 30th.

hVIVO Stock Up 3.4%

The company has a quick ratio of 1.16, a current ratio of 1.61 and a debt-to-equity ratio of 33.86. The firm has a market capitalization of £76.07 million, a PE ratio of 4.43 and a beta of 0.97. The company's fifty day simple moving average is GBX 15.92 and its 200 day simple moving average is GBX 17.70.

hVIVO (LON:HVO - Get Free Report) last announced its earnings results on Thursday, April 10th. The company reported GBX 1.69 ($0.02) EPS for the quarter. hVIVO had a return on equity of 47.93% and a net margin of 25.96%. Analysts anticipate that hVIVO plc will post 1.5492958 earnings per share for the current fiscal year.

hVIVO Company Profile

hVIVO plc operates as a pharmaceutical service and contract research company. The company is involved in testing vaccines and antivirals using human challenge clinical trials. It provides services to big pharma, biotech, government, and public health organizations. The company has a portfolio of human challenge study models for conditions, such as RSV, flu, human rhinovirus, asthma, malaria, cough, and COPD, as well as developing COVID-19 human challenge study model.